Mirtax

Quick links to important sections

Mirtax

Method of action: Miorelaxant, Muscle Relaxant

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mirtax

What is Mirtax?

Mirtax is a prescription medication primarily used in the treatment of major depressive disorder. It belongs to a class of drugs known as tetracyclic antidepressants. Unlike many other antidepressants that primarily inhibit the reuptake of neurotransmitters, Mirtax works through a distinct mechanism of action to balance brain chemistry.

Therapeutic Classification

Mirtax is categorized as a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA). This means it targets specific pathways in the central nervous system to increase the levels of certain natural substances that help maintain mental balance.

Primary Mechanism

The medication functions by enhancing the activity of two key neurotransmitters:

  • Norepinephrine: Involved in alertness, energy, and mood regulation.
  • Serotonin: Often referred to as a chemical messenger that stabilizes mood and feelings of well-being.

By blocking specific receptors—notably alpha-2 adrenergic receptors—Mirtax effectively releases a 'brake' on the brain's neurotransmitter systems, allowing for increased signaling in areas that regulate mood and emotional response. It also blocks certain serotonin receptors, which is intended to reduce common side effects associated with non-specific serotonin stimulation.

Clinical Application

Mirtax is used to alleviate the core symptoms of depression, which may include persistent sadness, loss of interest in activities, changes in appetite, and sleep disturbances. Because of its unique pharmacological profile, it is sometimes selected for patients who have not responded well to other classes of antidepressants, such as Selective Serotonin Reuptake Inhibitors (SSRIs).

What side effects are possible with Mirtax?

Possible side effects and safety information

The safety profile of Mirtax (Cyclobenzaprine Hydrochloride) is officially documented by government health authorities, describing adverse reactions primarily linked to its central nervous system (CNS) and anticholinergic effects.

Adverse Reaction Classification

Side effects are often categorized by frequency and the body system affected. The most frequently reported adverse reactions are classified as common in official prescribing information. These typically involve the Nervous System (e.g., somnolence, dizziness, fatigue) and the Gastrointestinal System (e.g., dry mouth, constipation, nausea, dyspepsia).

System-Organ Class Common Adverse Reactions (Examples)
Nervous System Disorders Somnolence, Dizziness, Fatigue
Gastrointestinal Disorders Dry Mouth, Constipation, Nausea

Serious Adverse Reactions and Safety Constraints

Regulatory documents include warnings for potentially serious adverse reactions. These include the risk of Serotonin syndrome when the medicine is used with other serotonergic agents, and potential Tricyclic Antidepressant-like effects on the heart, such as arrhythmias or myocardial infarction, due to its structural class. Hypersensitivity reactions, including anaphylaxis and angioedema, have also been reported.

Formal limitations govern the use of Mirtax. The medication is contraindicated in patients who are currently taking or have recently discontinued Monoamine Oxidase Inhibitors (MAOIs). It is also contraindicated in individuals with certain pre-existing heart conditions, like arrhythmias or congestive heart failure, and in those with hyperthyroidism. Due to increased susceptibility to effects, the drug is not recommended in older adults or in those with moderate to severe hepatic impairment. Official labels also state that use should be limited to short periods (up to two or three weeks), as long-term efficacy is not established.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose with Mirtax primarily by its effects on the Central Nervous System (CNS) and Cardiovascular System. Documented presentations include disorientation, drowsiness, and impaired memory, alongside cardiovascular signs such as tachycardia (fast heart rate).

Serious outcomes, including fatalities, have been reported, particularly at dosages higher than recommended, with the risk significantly increased in cases of mixed overdose—when Mirtax is taken with other pharmacological agents. Cardiovascular risks in overdose specifically include QT prolongation and Torsades de Pointes.

Patients with moderate to severe renal or hepatic impairment may have reduced drug clearance, which can lead to higher Mirtax levels in the body, potentially increasing overdose risk.

Required Emergency Action

Immediate medical help must be sought if an overdose is suspected. Specifically, emergency services should be called if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Healthcare professionals may administer activated charcoal to absorb the drug in cases of overdose. The decision to prescribe should mitigate the risk of intentional overdose related to the potential worsening of depression or suicidal thinking.

Therapeutic Uses of Mirtax

What Mirtax Treats: Therapeutic Areas of Use

The primary role of Mirtax is the management of symptoms associated with major depression. The medication is commonly used to help with symptomatic relief and is applied across domains where additional symptomatic support is needed to address co-occurring symptoms that interfere with daily comfort. Mirtax is frequently used across conditions characterized by episodic or fluctuating symptom patterns involving core affective distress, sleep disturbance, and vegetative symptoms like reduced appetite.

Supportive Symptom Management

The medication is relevant in clinical settings marked by heightened patient distress and emotional burden. It helps address symptom clusters that may become intense or disruptive, often used when symptoms create noticeable physiological strain and interfere with daily comfort. The support provided assists the patient during difficult episodes by easing distress and helps maintain functional stability during symptomatic periods.

Quick Fact: Therapeutic Support

Mirtax is used in situations involving certain distressing symptoms and is relevant when supportive symptom management is appropriate for conditions where symptoms may intensify temporarily.

Regulatory References

  1. NIH MedlinePlus Drug Information on Mirtazapine

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Mirtax — Official Regulatory Information

Mirtax (Cyclobenzaprine Hydrochloride) eligibility is strictly defined by government regulatory documents based on age, health status, and concurrent medication use.


Eligibility Scope

  • Populations for whom use is allowed (as stated in label):
    • Adults and adolescents ge 15 years of age for immediate-release tablets, used for short periods (up to 2 or 3 weeks).
  • Populations for whom use is not recommended (if applicable):
    • The elderly (ge 65 years) due to increased plasma levels and risk of CNS effects.
    • Patients with Moderate to Severe Hepatic Impairment (use is explicitly not recommended).
  • Populations for whom use is contraindicated:
    • Patients with Hypersensitivity to the drug or any component.
    • Patients who are receiving Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of stopping MAOIs.
    • Patients with Heart Block, Conduction Disturbances, Congestive Heart Failure (CHF), or in the acute recovery phase of a myocardial infarction.
    • Patients with Hyperthyroidism (overactive thyroid).

Age-Related and Condition-Specific Eligibility Rules

Classification Rule (Official Wording)
Pediatric Use Safety and effectiveness have not been established for children under 15 years of age.
Hepatic Function Use with Caution in Mild Hepatic Impairment; use Not Recommended in moderate-to-severe impairment.
Pregnancy Status Use is only if clearly needed; available data have not identified a drug-associated risk of major birth defects.
Conditional Use Caution is required for patients with Angle-Closure Glaucoma or history of Urinary Retention.

What should I know about interactions with other medicines?

Mirtax (Cyclobenzaprine Hydrochloride) is subject to specific interaction patterns with other medicines and products, as documented in official regulatory labeling. Co-administration is contraindicated with Monoamine Oxidase Inhibitors (MAOIs); Mirtax must not be taken within 14 days of discontinuing an MAOI. This restriction is mandated due to the risk of severe, life-threatening hyperpyretic crisis or seizures.

The drug carries a recognized risk of Serotonin Syndrome when combined with other Serotonergic Drugs, such as certain antidepressants (SSRIs, SNRIs) and tramadol. The effects of alcohol and other CNS Depressants (including barbiturates and opioids) may be enhanced, resulting in increased risk of pronounced central nervous system effects. Furthermore, combining Mirtax with anticholinergic medications increases the likelihood of additive effects, such as urinary retention.

Regulatory data also define constraints related to drug exposure. Use is not recommended for elderly patients or individuals with hepatic impairment, as official studies show a significant, documented increase in plasma concentrations ( AUC) in these populations. For the extended-release capsule, ingestion with a high-fat meal has been found to increase the peak plasma concentration (C max) and overall drug exposure.

Mechanism of Action

Mirtax functions as a selective antagonist of the H1 (histamine type 1) and 5-HT2A (serotonin type 2A) receptors. It mediates receptor antagonism by competitively binding to these sites, which prevents endogenous neurotransmitters from activating the receptors. This binding results in altered intracellular signaling cascades within affected neurons.

The compound also exhibits a moderate affinity for the alpha2-adrenergic receptors, leading to the modulation of central adrenergic signaling. These varied interactions collectively influence downstream monoaminergic activity, primarily through the strong antagonistic action on H1 and 5-HT2A receptor pathways, thereby changing neurotransmitter release and receptor firing rates in various brain regions.

Dosage and Administration Information

How to Use Mirtax (Cyclobenzaprine)

Mirtax (Cyclobenzaprine Hydrochloride) is administered exclusively by the oral route, defining the fundamental method of its use. This medication is intended for short-term use only, with the duration of treatment generally limited to two or three weeks.


Administration Patterns and Dosage

Use of Mirtax is structured around two distinct oral formulations, each with a specific frequency pattern:

  • Immediate-Release (IR) Tablets are generally taken three times a day (t.i.d.). The typical initial dose is 5 mg, which may be increased to a maximum of 10 mg three times daily (30 mg total).
  • Extended-Release (ER) Capsules are administered once daily, with a recommended starting dose of 15 mg. This may be increased to a maximum dose of 30 mg once daily.

Administration Conditions and Population Rules

Proper administration of Mirtax depends on adherence to specific intake conditions, particularly for the ER formulation. ER capsules should be taken at approximately the same time each day and must be swallowed intact. Alternatively, the capsule contents can be mixed with a tablespoon of applesauce and swallowed immediately, but the granules must not be chewed.

Specific dosage rules apply to certain patient groups. For older adults and patients with mild hepatic impairment, therapy with the IR tablet should be initiated with the lowest dose of 5 mg and titrated slowly. The use of the ER formulation is not generally recommended in patients with moderate or severe hepatic impairment due to increased drug exposure.

Recent Clinical Evidence

Research evidence / Overview of Studies for Mirtax


Evidence from Core Clinical Trials for Acute Muscle Spasms

The research base for Mirtax (Cyclobenzaprine) primarily includes short-term Randomized Controlled Trials (RCTs). These trials were applied in studies examining patient-reported experiences of adults dealing with acute, painful muscle spasms. Research examined the use of the drug as an adjunct to rest and physical therapy. The studies monitored outcomes related to physical discomfort, including measurements of patient-reported pain scores and subjective assessments of muscle tightening. Functional outcomes, such as changes in range of motion and limitations in daily activity, were also measured.

Studies report how symptoms evolved in the observed populations, and research describes group patterns across the measured outcomes, generally within the short-term observation period. The research structure for these core findings is broadly categorized as High evidence level; however, this level relates specifically to research examining the initial, acute phase of muscle spasm.


Research on Comparative Approaches

Research has explored comparative scenarios through Head-to-head Randomized Controlled Trials and systematic reviews. Studies examined the drug against an inactive substance (placebo) and other active pharmacological agents, such as other muscle relaxants. Research examined outcomes related to physical discomfort and how these were reported across groups receiving the drug versus comparators, including measurements of pain and spasm severity.

Some trials described patterns related to symptom changes between those receiving the drug and those receiving placebo. When compared directly against other active medicines, the findings were mixed. Comparative research explored patterns in patient-reported outcomes, including both symptom measurements and tolerability, across different treatments studied. The quality of comparative evidence varies across studies due to heterogeneity in design and protocols.


Long-Term Evidence and Duration of Follow-Up

Mirtax was studied for acute conditions, and consequently, the follow-up durations were limited, typically concluding within one to three weeks. Due to this short study design focusing on the immediate treatment period, long-term outcomes are not fully established. Available evidence provides limited information for long-term outcomes, such as sustained measurements of activity level or symptom patterns beyond the acute phase.


Synthesis of Research Certainty and Remaining Gaps

The research exploring short-term symptom changes was evaluated in a structure that is broadly categorized as High evidence level, reflecting the consistent study design (RCTs) used for observations. However, this high evidence level applies only to the specific conditions under which the research was conducted—namely, as an adjunct to rest and physical therapy during the acute phase. Comparative evidence is lacking for many other therapeutic strategies, and data for certain groups, such as children or older adults, remain insufficient in the core documentation.

Frequently Asked Questions (FAQ)

Common questions about Mirtax (FAQ)


Q: Is Mirtax considered a sedating antidepressant?

A: Mirtax (Cyclobenzaprine) is formally classified as a Centrally Acting Skeletal Muscle Relaxant, not an antidepressant. However, due to its chemical structure, it is related to the tricyclic family of drugs. The official product information notes that drowsiness and somnolence are common side effects, suggesting the medication may contribute to sedation.


Q: Why is drowsiness or feeling sleepy often listed as a common side effect of Mirtax?

A: Official regulatory documents indicate that the drowsiness associated with Mirtax is linked to its mechanism of action. The drug acts as a strong antagonist of histamine \mathbfH1 receptors in the central nervous system. This specific documented action is understood to be a contributing factor to the common side effect of drowsiness.


Q: Does Mirtax cause dizziness or lightheadedness upon standing?

A: Postmarketing reports include potential events like hypotension, which is low blood pressure. Because hypotension may result in symptoms such as lightheadedness or dizziness when changing position, this relationship is noted in the safety information.


Q: What information is available about potential effects of Mirtax on blood pressure?

A: According to postmarketing reports, potential effects on the cardiovascular system have been noted. These reports include instances of hypotension (low blood pressure) and tachycardia (an abnormally fast heart rate).


Q: Can Mirtax potentially affect liver enzyme levels?

A: Official postmarketing data has indicated potential adverse effects on the liver. These reports include changes in laboratory results, such as abnormal liver function tests. Postmarketing reports also include isolated instances of more serious hepatic events, such as hepatitis and jaundice.


Q: Are there specific over-the-counter medicines or supplements that can interact with Mirtax?

A: The drug label advises caution regarding the combination of Mirtax with other products. It is stated that interactions are possible with certain over-the-counter (OTC) medicines, herbal products, and other supplements. Such combinations may lead to enhanced central nervous system effects or increase the documented risk of Serotonin Syndrome.


Q: Can Mirtax interact with medications used for migraines, such as triptans?

A: Official documents warn against the use of Mirtax with certain serotonergic drugs. This category includes some medicines used to treat migraines, such as triptans. Combining these medications carries a serious risk of Serotonin Syndrome.


Q: What is "serotonin syndrome," and how is it related to Mirtax interactions?

A: Serotonin Syndrome is a potentially serious condition linked to excessive serotonin activity in the nervous system. Symptoms described in regulatory warnings can include confusion, agitation, a fast heartbeat, sweating, and muscle rigidity. Mirtax can increase the risk of this condition when combined with other serotonergic medications.


Q: Are there any restrictions on diet or food when taking Mirtax?

A: Official instructions mention that the extended-release capsule should be taken with caution regarding food. Specifically, taking it with a high-fat meal may increase the amount of medicine absorbed by the body. However, the standard immediate-release tablets can be administered with or without food.


Q: What does the term 'tetracyclic' mean in relation to Mirtax?

A: Mirtax (Cyclobenzaprine) is structurally defined as a dibenzocycloheptene derivative. While some references may use the term 'tetracyclic,' the official labeling classifies it as a tricyclic amine salt. This structure places the medication in a chemical class similar to tricyclic antidepressant compounds.


Q: How long does it typically take to start noticing the effects of Mirtax?

A: According to authoritative drug information, the muscle relaxant effects of the immediate-release tablet may begin relatively quickly. This onset of effect is typically observed within 30 minutes to one hour after the medication is taken.


Q: What should be done if a dose of Mirtax is missed?

A: Official information on administration advises that if a dose is missed, it should be taken as soon as possible. However, if it is close to the time of the next scheduled dose, the missed dose should be skipped entirely. Doubling the dose to compensate is not recommended by regulatory guidelines.


Q: Is weight gain a common documented side effect of Mirtax?

A: According to the clinical trial data reviewed by government health authorities, weight gain is not listed among the most frequently reported adverse reactions. The common side effects are noted as those occurring in 3% or more of patients.


Q: Are there specific side effects associated with long-term use of Mirtax?

A: Mirtax is approved only for short-term use, typically two to three weeks, as long-term efficacy is not established by official studies. Extended use carries a documented risk of developing physical dependence. Because of this, abrupt discontinuation after prolonged use can lead to potential withdrawal symptoms.


Q: Does Mirtax cause vivid or unusual dreams?

A: Postmarketing experience reports have included some psychiatric adverse reactions. These reports include occurrences of abnormal dreaming and hallucinations.


Q: Can Mirtax affect a person's appetite?

A: Official postmarketing surveillance reports have noted the possibility of effects on the gastrointestinal system, specifically mentioning anorexia. Anorexia is described as a loss of appetite.


Q: How is the risk of suicidal thoughts described in official warnings for Mirtax?

A: Post-marketing surveillance reports submitted to regulatory agencies have identified potential risks associated with suicidal behavior and related mood changes. The official warnings emphasize the need for careful observation and monitoring while taking this medication.


Q: Is restlessness or an urge to move (akathisia) commonly reported when starting Mirtax?

A: While restlessness is noted as a symptom of overdose, postmarketing experience reports have also included general symptoms such as nervousness and agitation. These effects are categorized under psychiatric or nervous system disorders.


Q: Is St. John's Wort safe to take concurrently with Mirtax?

A: Official drug interaction information describes the potential risk when combining Mirtax with any serotonergic substance. Because the herbal supplement St. John's Wort has been described as having serotonergic properties, using it with Mirtax may increase the risk of Serotonin Syndrome.


Q: Is there an interaction risk with Mirtax and seizure medications?

A: Regulatory documents warn that the risk of a seizure may be enhanced when Mirtax is used concurrently with certain medications. For example, the FDA label specifically notes this enhanced risk when the drug is combined with certain medications, such as tramadol, which are also known to lower the seizure threshold.


Q: Are there special considerations for using Mirtax in people with kidney problems?

A: Official drug information states there are no specific dosing guidelines provided for Mirtax use in people with kidney impairment. However, since the drug is extensively metabolized and excreted by the kidneys, general caution is advised due to the potential for increased drug levels in the body.


Q: Can people with a history of seizures safely use Mirtax?

A: Regulatory precautions note that Mirtax should be used with caution in individuals who have a history of seizures, as official documents suggest the drug may potentially worsen this pre-existing condition.


Q: Is Mirtax known to pass into breast milk?

A: According to official regulatory information, it is not known whether the drug is excreted into human breast milk. However, because Mirtax is chemically related to tricyclic antidepressant compounds, which are known to pass into milk, caution is generally advised.


Q: What are the official cautions for Mirtax use in people with diabetes?

A: There is no specific caution for Mirtax use in people with diabetes noted in the main product label. However, official information describes the medication's primary route of excretion is through the kidney. Since some patients with diabetes may have impaired kidney function, this is a relevant factor for a healthcare provider to consider.


Q: Is there a generic version of Mirtax available?

A: Official records confirm that the active ingredient in Mirtax, Cyclobenzaprine Hydrochloride, is widely available in generic formulations. These generic forms include both standard tablets and extended-release capsules.


Q: Are there any known withdrawal symptoms if Mirtax is stopped suddenly?

A: Stopping Mirtax suddenly, particularly after prolonged use, may be associated with the potential for withdrawal symptoms. Regulatory documents list symptoms that may include nausea, headache, and malaise (general feeling of discomfort).


Q: What are the general recommendations for monitoring health while taking Mirtax?

A: Official recommendations emphasize that a healthcare provider should check progress at regular visits to monitor for any potential problems. This monitoring may include blood tests to check for unwanted effects, as deemed necessary by the provider.

How should Mirtax be stored and disposed of?

How to Store and Dispose of Mirtax (Cyclobenzaprine Hydrochloride)

Official regulatory guidelines define specific conditions for the storage and disposal of Mirtax tablets to maintain product stability and safety.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at Controlled Room Temperature (CRT), mathbf68 F to mathbf77 F (mathbf20 C to mathbf25 C).
Environment Keep from freezing and store away from moisture, heat, and direct light.
Packaging Keep the medicine in its original container, ensuring the container is tightly closed.
Child Safety The medication must be kept out of the sight and reach of children in a secure, up and away location.

Disposal Instructions

Unused or expired Mirtax should not be flushed down the toilet or disposed of in household wastewater. The recommended procedure involves using an official drug take-back program. If no program is available, unused tablets must be rendered unusable by mixing them with an undesirable substance (e.g., dirt, coffee grounds) and placed in a sealed container before discarding in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mirtax found in:

A-Z Index: